NASC
Can B Corp
$0.02
0.00 (-6.25%)
At close · Jul 2
Market Cap
$1.14M
Shares
75,841,988
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.02
Open$0.02
Day$0.02–0.02
52W$0.01–0.04
Avg vol 30d31K
Short int41 · 0.0% float · 1.0d
Short vol34%
DataJan 2020–Jul 2026
Filing10-Q · Nov 19
Equibles Rating
blended score · not investment advice
Overall
Buy
Technical · trend & momentum
Buy
◦
50 / 200-day cross
no cross
−
Price vs 200-day avg
−13% below
+
Price vs 50-day avg
+4% above
◦
RSI (14)
54 · neutral
+
MACD trend
positive
◦
52-week position
19% · mid-range
Sentiment · smart money
Bearish
◦
Trend (MA cross)
50d $0 › 200d $0 — 200d above 50d
◦
Institutional flow
No 13F holder data
◦
Insider flow
No net insider activity over 90 days
−
Short interest
0.00% of float · ▲ +4000.0% MoM · 1.0 days cover
◦
Volume signal
Volume near normal
◦
Institution breadth
No 13F holder history
Fundamentals
Excellent
+
Revenue growth
+29% Y/Y
+
Gross margin
292%, contracting
+
EPS growth
+82% Y/Y
−
Free cash flow
$-1.3M
+
Balance sheet
net cash $34.0K
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Nov 19, 2024
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
−13% below
Bearish
Price vs 50-day avg
+4% above
Bullish
RSI (14)
54 · neutral
Neutral
MACD trend
positive
Bullish
52-week position
19% · mid-range
Neutral
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.00% of float · ▲ +4000.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Price context
position in its 52-week range
52-wk low $0
Now $0 · 19%
52-wk high $0
vs 200-day avg -13%
vs 50-day avg +4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NASC
this stock
Can B Corp
|
$1.14M | -6.3% | +29.0% | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$52.99B | +7.6% | — | — | 0.3% |
|
GALDY
Galderma Group AG/ADR
|
$52.48B | +8.0% | — | — | 0.0% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$45.13B | — | — | — | 0.0% |
|
HLN
Haleon plc
|
$43.25B | -2.9% | — | — | 0.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionShort & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NASC | +36.4% | -11.8% | -11.8% | -6.3% | -6.3% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | +34.9% | -10.5% | -19.8% | -6.0% | -15.5% |